While adult studies have had mixed results, HDAC inhibitors can be safely combined with other agents such as DNMT inhibitors and relapse regimens and are currently being investigated in relapsed pediatric AML (NCT03263936) [73, 74]. Here, HDAC9 is linked to acute myeloid leukemia.